HealthyNCT04890470
Effects of Oxytocin and Vasopressin on Moral Decision Making
A study testing Oxytocin and Vasopressin in people with Healthy, run by University of Electronic Science and Technology of China at 1 site in China.
Trial summary
To determine whether the neuropeptide oxytocin (OXT) and vassopressin (AVP) influence moral decision making Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Oxytocin and Vasopressin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 180 participants
- Where
- 1 siteChina
- Study dates
- 2 Mar 2021to 12 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy subjects without past or current psychiatric or neurological disorders
Who cannot join
- pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
To determine whether the neuropeptide oxytocin (OXT) and vassopressin (AVP) influence moral decision making
Read the detailed description
In a double-blind, between- subject placebo (PLC) controlled design, subjects will first complete a series of questionnaires in terms of mood, clinical symptoms, and traits. After that their moral judgment and emotion towards both verbal descriptions of moral dilemma scenarios and pictures of specific interpersonal ones will be assessed and the effect of intranasal OXT and AVP between both male and female healthy subjects will be investigated.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OxytocinDrug
intranasal administration of oxytocin (24 IU)
VasopressinDrug
intranasal administration of vasopressin (20 IU)
PlaceboDrug
intranasal administration of placebo
| Study group | Role | What they receive |
|---|---|---|
| oxytocin group | Experimental | subjects with oxytocin treatment Receives: Drug: Oxytocin |
| vasopressin group | Experimental | subjects with vasopressin treatment Receives: Drug: Vasopressin |
| placebo group | Placebo comparator | subjects with placebo treatment Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect of OXT and AVP on behavioral index of moral decision task
intensity of feelings
Measured: 45 mins - 105 mins
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 May 2021
- Study start2 Mar 2021
- Primary completion12 Dec 2022
- Study completion12 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 180 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Electronic Science and Technology of China
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Keith Kendrick, University of Electronic Science and Technology of China
- Investigators
- Keith M. Kendrick, Principal investigator, University of Electronic Science and Technology of China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04890470
- Sponsor's protocol ID
- UESTC-neuSCAN-78
- Status last verified
- Sep 2023
- First submitted
- 12 May 2021
- Last updated
- 21 Sep 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Zheng X, Wang J, Yang X, Xu L, Becker B, Sahakian BJ, Robbins TW, Kendrick KM. Oxytocin, but not vasopressin, decreases willingness to harm others by promoting moral emotions of guilt and shame. Mol Psychiatry. 2024 Nov;29(11):3475-3482. doi: 10.1038/s41380-024-02590-w. Epub 2024 May 20.
PubMed 38769372
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Oxytocin and Vasopressin on Moral Decision Making
- ClinicalTrials.gov ID
- NCT04890470
- Acronym / sponsor ID
- UESTC-neuSCAN-78
- Conditions
- Healthy
- Keywords
- moral decision making, oxytocin, vasopressin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 180 participants (actual)
- Lead sponsor
- University of Electronic Science and Technology of ChinaUniversity, hospital or other
- Study start
- 2 Mar 2021 (actual)
- Primary completion
- 12 Dec 2022 (actual)
- Study completion
- 12 Dec 2022 (actual)
- First posted
- 18 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine whether the neuropeptide oxytocin (OXT) and vassopressin (AVP) influence moral decision making
Detailed description
In a double-blind, between- subject placebo (PLC) controlled design, subjects will first complete a series of questionnaires in terms of mood, clinical symptoms, and traits. After that their moral judgment and emotion towards both verbal descriptions of moral dilemma scenarios and pictures of specific interpersonal ones will be assessed and the effect of intranasal OXT and AVP between both male and female healthy subjects will be investigated.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| oxytocin group | Experimental | Drug: Oxytocinsubjects with oxytocin treatment |
| vasopressin group | Experimental | Drug: Vasopressinsubjects with vasopressin treatment |
| placebo group | Placebo comparator | Drug: Placebosubjects with placebo treatment |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- healthy subjects without past or current psychiatric or neurological disorders
Key exclusion criteria (1 listed)
- pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oxytocinintranasal administration of oxytocin (24 IU) | Drug | oxytocin group |
| Vasopressinintranasal administration of vasopressin (20 IU) | Drug | vasopressin group |
| Placebointranasal administration of placebo | Drug | placebo group |
Primary outcome
Effect of OXT and AVP on behavioral index of moral decision task
Time frame: 45 mins - 105 mins
intensity of feelings
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2023.
- Derived from this study: PubMed 38769372Zheng X, Wang J, Yang X, Xu L, Becker B, Sahakian BJ, Robbins TW, Kendrick KM. Oxytocin, but not vasopressin, decreases willingness to harm others by promoting moral emotions of guilt and shame. Mol Psychiatry. 2024 Nov;29(11):3475-3482. doi: 10.1038/s41380-024-02590-w. Epub 2024 May 20.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Keith M. Kendrick principal investigator
University of Electronic Science and Technology of China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Oxytocin and Vasopressin in people with Healthy, run by University of Electronic Science and Technology of China at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect of OXT and AVP on behavioral index of moral decision task (time frame: 45 mins - 105 mins). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04890470, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.